Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP365471.RA18nZCY3qWcdpQ7MKWcuRPyYbjZbQw7sD7LYUMJ735zU130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP365471.RA18nZCY3qWcdpQ7MKWcuRPyYbjZbQw7sD7LYUMJ735zU130_provenance.
• NP826374.RAofpGltJKkSBeiOTpgxr_8usAsphvxk8siL8HoA6Y9d4130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826374.RAofpGltJKkSBeiOTpgxr_8usAsphvxk8siL8HoA6Y9d4130_provenance.
• NP632463.RAyoLRpmI7LmBBJsTVSfmPkhrlJ8rKE4RmmxtJZ1K-CFg130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632463.RAyoLRpmI7LmBBJsTVSfmPkhrlJ8rKE4RmmxtJZ1K-CFg130_provenance.
• NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
• NP468938.RAeR-J67rxicitUi5ZuLFxHbIXm50wzGij6xBw48iNdAE130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468938.RAeR-J67rxicitUi5ZuLFxHbIXm50wzGij6xBw48iNdAE130_provenance.
• NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468940.RAcrradOVnAjNAZ1ELmCbiVvLrMYuDCRUsDfK3-9jbujM130_provenance.
• NP468941.RAUvfoMeY_y1-Xb8gI7Rqkatrfz6iMHBvDdlNM3aIW9fE130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468941.RAUvfoMeY_y1-Xb8gI7Rqkatrfz6iMHBvDdlNM3aIW9fE130_provenance.
• NP895701.RANvW9xwq46eOlWENJ5qMMAnEV5CF6OScp9kq0OSOHU-s130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP895701.RANvW9xwq46eOlWENJ5qMMAnEV5CF6OScp9kq0OSOHU-s130_provenance.
• NP247820.RA09AUNZI632bHNQldMgZRAc8S5pvF5gNkMxoyL0wzL-0130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP247820.RA09AUNZI632bHNQldMgZRAc8S5pvF5gNkMxoyL0wzL-0130_provenance.
• NP895261.RAKiZLjaC8-hDzZueBdSmLJaSSqu_6SIk3Q68e6MRk4YA130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP895261.RAKiZLjaC8-hDzZueBdSmLJaSSqu_6SIk3Q68e6MRk4YA130_provenance.
• NP648936.RAxUw-Uxfy3nsTvoH9H8Iujo06VqI_1D5yK7ZE75XXNMY130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP648936.RAxUw-Uxfy3nsTvoH9H8Iujo06VqI_1D5yK7ZE75XXNMY130_provenance.
• NP468945.RAI2hODaQ8GbMvIOVxaqCJSPdJBQZlIiNHEnaxoQ0McrU130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468945.RAI2hODaQ8GbMvIOVxaqCJSPdJBQZlIiNHEnaxoQ0McrU130_provenance.
• NP825619.RA6inLuX6fj5E9ONfOf_I2ZexrWGq0tOgazp7DEOu6Zv4130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825619.RA6inLuX6fj5E9ONfOf_I2ZexrWGq0tOgazp7DEOu6Zv4130_provenance.
• NP468936.RA60GEUVxG57mJnZODgH_NVlDSTrwJmTTcNWa6lalH0RE130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468936.RA60GEUVxG57mJnZODgH_NVlDSTrwJmTTcNWa6lalH0RE130_provenance.